Dasatinib
Total Payments
$220,046
Transactions
49
Doctors
3
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $24,898 | 3 | 1 |
| 2023 | $60,726 | 11 | 2 |
| 2022 | $87,652 | 24 | 3 |
| 2021 | $5,500 | 2 | 1 |
| 2020 | $17,999 | 5 | 2 |
| 2018 | $12,771 | 3 | 1 |
| 2017 | $10,500 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $95,676 | 23 | 43.5% |
| Honoraria | $61,300 | 12 | 27.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $33,670 | 3 | 15.3% |
| Consulting Fee | $28,400 | 6 | 12.9% |
| Food and Beverage | $1,000 | 5 | 0.5% |
Ad
Manufacturing Companies
- Hikma Pharmaceuticals USA $196,775
- West-Ward Pharmaceuticals $23,271
Product Information
- Type Drug
- Total Payments $220,046
- Total Doctors 3
- Transactions 49
About Dasatinib
Dasatinib is a drug associated with $220,046 in payments to 3 healthcare providers, recorded across 49 transactions in the CMS Open Payments database. The primary manufacturer is Hikma Pharmaceuticals USA.
Payment data is available from 2017 to 2024. In 2024, $24,898 was paid across 3 transactions to 1 doctors.
The most common payment nature for Dasatinib is "Travel and Lodging" ($95,676, 43.5% of total).